仁度生物
(688193)
| 流通市值：20.91亿 | | | 总市值：20.91亿 |
| 流通股本：4006.99万 | | | 总股本：4006.99万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 79,437,446.03 | 42,078,944.06 | 161,942,569.09 | 119,154,895.95 |
| 营业收入 | 79,437,446.03 | 42,078,944.06 | 161,942,569.09 | 119,154,895.95 |
| 二、营业总成本 | 79,157,307.6 | 40,002,823.79 | 180,039,662.39 | 131,604,403.33 |
| 营业成本 | 16,834,306.55 | 10,012,421.26 | 35,561,286.71 | 26,511,727.4 |
| 税金及附加 | 1,192,524.88 | 600,013.72 | 2,095,063.47 | 1,503,703.15 |
| 销售费用 | 35,373,385.34 | 16,862,704.56 | 77,700,093.58 | 58,192,657.32 |
| 管理费用 | 12,725,803.25 | 5,814,291.51 | 31,334,705.58 | 20,802,399.82 |
| 研发费用 | 13,014,140.93 | 6,687,643.81 | 34,590,668.4 | 25,647,407.63 |
| 财务费用 | 17,146.65 | 25,748.94 | -1,242,155.35 | -1,053,491.99 |
| 其中:利息费用 | 104,739.45 | 49,666.83 | 236,404.11 | 194,224.74 |
| 其中:利息收入 | 208,088.62 | 73,374.2 | 1,604,758.94 | 1,274,417.87 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -1,317,068 | 247,357.32 | 3,624,066.22 | 4,249,405.63 |
| 加:投资收益 | 8,462,073.29 | 3,393,178.06 | 10,106,748.06 | 6,431,926.46 |
| 资产处置收益 | 14,898.14 | 14,898.14 | -386,313.64 | -386,313.64 |
| 资产减值损失(新) | -621,844.51 | -394,691.92 | -1,947,447.67 | -1,351,284.39 |
| 信用减值损失(新) | -255,640.23 | -222,448.07 | 12,055,316.99 | 7,237,872.96 |
| 其他收益 | 4,076,082.81 | 660,233.5 | 5,068,756.28 | 3,795,065.18 |
| 四、营业利润 | 10,638,639.93 | 5,774,647.3 | 10,424,032.94 | 7,527,164.82 |
| 加:营业外收入 | 14,690.27 | 14,690.27 | 53,620.87 | 53,620.87 |
| 减:营业外支出 | 326,725.66 | 319,033.35 | 258,610.28 | 238,885.36 |
| 五、利润总额 | 10,326,604.54 | 5,470,304.22 | 10,219,043.53 | 7,341,900.33 |
| 减:所得税费用 | 751,084.67 | 474,900.3 | 131,657.33 | 328,178.76 |
| 六、净利润 | 9,575,519.87 | 4,995,403.92 | 10,087,386.2 | 7,013,721.57 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 9,575,519.87 | 4,995,403.92 | 10,087,386.2 | 7,013,721.57 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 9,575,519.87 | 4,995,403.92 | 10,087,386.2 | 7,013,721.57 |
| 扣除非经常损益后的净利润 | 1,370,518.29 | 2,146,977.05 | -11,708,894.3 | -7,724,813.05 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.27 | 0.12 | 0.26 | 0.18 |
| (二)稀释每股收益 | 0.27 | 0.12 | 0.26 | 0.18 |
| 八、其他综合收益 | -1,025,542.49 | -521,780.89 | -812,996.32 | -428,869.26 |
| 归属于母公司股东的其他综合收益 | -1,025,542.49 | -521,780.89 | -812,996.32 | -428,869.26 |
| 九、综合收益总额 | 8,549,977.38 | 4,473,623.03 | 9,274,389.88 | 6,584,852.31 |
| 归属于母公司股东的综合收益总额 | 8,549,977.38 | 4,473,623.03 | 9,274,389.88 | 6,584,852.31 |
| 公告日期 | 2026-08-29 | 2026-04-29 | 2026-04-29 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |